Abstract

The main causes of death in patients with chronic kidney disease (CKD) are of cardiovascular nature. The interaction between traditional cardiovascular risk factors (CVRF) and non-traditional risk factors (RF) triggers various complex pathophysiological mechanisms that will lead to accelerated atherosclerosis in the context of decreased renal function. In terms of mortality, CKD should be considered equivalent to ischemic coronary artery disease (CAD) and properly monitored. Vascular calcification, endothelial dysfunction, oxidative stress, anemia, and inflammatory syndrome represents the main uremic RF triggered by accumulation of the uremic toxins in CKD subjects. Proteinuria that appears due to kidney function decline may initiate an inflammatory status and alteration of the coagulation—fibrinolysis systems, favorizing acute coronary syndromes (ACS) occurrence. All these factors represent potential targets for future therapy that may improve CKD patient’s survival and prevention of CV events. Once installed, the CAD in CKD population is associated with negative outcome and increased mortality rate, that is the reason why discovering the complex pathophysiological connections between the two conditions and a proper control of the uremic RF are crucial and may represent the solutions for influencing the prognostic. Exclusion of CKD subjects from the important trials dealing with ACS and improper use of the therapeutical options because of the declined kidney functioned are issues that need to be surpassed. New ongoing trials with CKD subjects and platelets reactivity studies offers new perspectives for a better clinical approach and the expected results will clarify many aspects.

Highlights

  • Stable ischemic coronary artery disease (CAD) and acute coronary syndromes (ACS) have a high incidence in the general population

  • This review aims to present the current knowledge of accelerated ACS in patients with Chronic kidney disease (CKD)

  • The keywords mentioned at the beginning of this paper (“atherosclerosis in chronic kidney disease”, “acute coronary syndromes in chronic kidney disease”, “non-traditional risk factors”, etc.)

Read more

Summary

Introduction

Stable ischemic coronary artery disease (CAD) and ACS have a high incidence in the general population. The mortality rate induced by coronary heart disease is significant, imposing a constant update and improvement of diagnostic and treatment algorithms [1]. Chronic kidney disease (CKD), in all stages of evolution, is associated with a significant cardiovascular risk (CVR), and patients diagnosed with this condition are more likely to develop ACS or malignant rhythm disorders with a fatal prognosis. The deaths of patients with CKD are predominantly caused by cardiovascular (CV) comorbidities and less by the progression of kidney disease. Patients with end-stage CKD have a CV death rate of approximately 50% [2]. According to the American Heart Association Councils on Kidney in Cardiovascular

Objectives
Methods
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call